Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2021). Universal Coronavirus Vaccines—An Urgent Need. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMp2118468

Regev-Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S., Meltzer, L., Asraf, K., Cohen, C., Fluss, R., Biber, A., Nemet, I., Kliker, L., Joseph, G., Doolman, R., Mendelson, E., Freedman, L. S., Harats, D., Kreiss, Y., & Lustig, Y. (2022). 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC (p. 2022.02.15.22270948). medRxiv. https://doi.org/10.1101/2022.02.15.22270948

Lipsitch, M., Krammer, F., Regev-Yochay, G., Lustig, Y., & Balicer, R. D. (2021). SARS-CoV-2 breakthrough infections in vaccinated individuals: Measurement, causes and impact. Nature Reviews Immunology, 1–9. https://doi.org/10.1038/s41577-021-00662-4

Gollub, R. L. (2022). Brain changes after COVID revealed by imaging. Nature. https://doi.org/10.1038/d41586-022-00503-x

Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., Lee, G. S., Choi, S. K., Takhar, H. S., Aragones, M., & Qian, L. (2022). Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nature Medicine, 1–1. https://doi.org/10.1038/s41591-022-01753-y

Benjamin Meyer. (2022, January 14). Here is a bit of a longer explanatory thread on our recent paper on “Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron”. You can read the full paper here: Https://t.co/R2FSyck6Nn [Tweet]. @BenjaminMeyer85. https://twitter.com/BenjaminMeyer85/status/1482102496764039176

Academics: Viral Evolution Scenarios, 10 February 2022. (n.d.). GOV.UK. Retrieved February 14, 2022, from https://www.gov.uk/government/publications/academics-viral-evolution-scenarios-10-february-2022

Niegowska, M., Wajda-Cuszlag, M., Stępień-Ptak, G., Trojanek, J., Michałkiewicz, J., Szalecki, M., & Sechi, L. A. (2019). Anti-HERV-WEnv antibodies are correlated with seroreactivity against Mycobacterium avium subsp. Paratuberculosis in children and youths at T1D risk. Scientific Reports, 9(1), 6282. https://doi.org/10.1038/s41598-019-42788-5

Kozlov, M. (2022). How does Omicron spread so fast? A high viral load isn’t the answer. Nature. https://doi.org/10.1038/d41586-022-00129-z

Zaidi, A. K., & Dehgani-Mobaraki, P. (2021). RETRACTED ARTICLE: The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article. The Journal of Antibiotics, 1–1. https://doi.org/10.1038/s41429-021-00430-5

Yonker, L. M., Boucau, J., Regan, J., Choudhary, M. C., Burns, M. D., Young, N., Farkas, E. J., Davis, J. P., Moschovis, P. P., Bernard Kinane, T., Fasano, A., Neilan, A. M., Li, J. Z., & Barczak, A. K. (2021). Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children. The Journal of Infectious Diseases, 224(11), 1821–1829. https://doi.org/10.1093/infdis/jiab509

Chertow, Daniel, Sydney Stein, Sabrina Ramelli, Alison Grazioli, Joon-Yong Chung, Manmeet Singh, Claude Kwe Yinda, et al. ‘SARS-CoV-2 Infection and Persistence throughout the Human Body and Brain’, 28 December 2021. https://doi.org/10.21203/rs.3.rs-1139035/v1.

Wheatley, A. K., & Juno, J. A. (2021). COVID-19 vaccines in the age of the delta variant. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00688-5

Nature Portfolio on Twitter. (n.d.). Twitter. Retrieved 14 November 2021, from https://twitter.com/NaturePortfolio/status/1459144019016040452

Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., House, T., Hay, J., Bell, J. I., Newton, J. N., Farrar, J., Crook, D., Cook, D., Rourke, E., Studley, R., Peto, T. E. A., Diamond, I., & Walker, A. S. (2021). Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nature Medicine, 1–9. https://doi.org/10.1038/s41591-021-01548-7

Kennedy-Shaffer, L., Kahn, R., & Lipsitch, M. (2021). Estimating Vaccine Efficacy Against Transmission via Effect on Viral Load. Epidemiology (Cambridge, Mass.), 32(6), 820–828. https://doi.org/10.1097/EDE.0000000000001415

Peeples, L. (2021). COVID reinfections likely within one or two years, models propose. Nature. https://doi.org/10.1038/d41586-021-02825-8

Gregory, A., & Weale, S. (2021, September 28). Covid: 37% of people have symptoms six months after infection. The Guardian. https://www.theguardian.com/world/2021/sep/28/covid-37-of-people-have-symptoms-six-months-after-infection

Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021). Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Science Immunology. https://doi.org/10.1126/sciimmunol.abl4509

Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., Hernán, M. A., Lipsitch, M., Kohane, I., Netzer, D., Reis, B. Y., & Balicer, R. D. (2021). Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2110475

Davis, H. E., Assaf, G. S., McCorkell, L., Wei, H., Low, R. J., Re’em, Y., Redfield, S., Austin, J. P., & Akrami, A. (2021). Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine, 0(0). https://doi.org/10.1016/j.eclinm.2021.101019

Al-Aly, Z., Xie, Y., & Bowe, B. (2021). High-dimensional characterization of post-acute sequelae of COVID-19. Nature, 594(7862), 259–264. https://doi.org/10.1038/s41586-021-03553-9

Lee Kennedy-Shaffer. (2021, May 6). .@rebeccajk13 and @mlipsitch showed how to use that to estimate efficacy against prevalent infection (https://t.co/LeXxqcumGS). [Tweet]. @LeeKShaffer. https://twitter.com/LeeKShaffer/status/1390322501817880581

Lipsitch, M., & Kahn, R. (2021). Interpreting vaccine efficacy trial results for infection and transmission. Vaccine, 39(30), 4082–4088. https://doi.org/10.1016/j.vaccine.2021.06.011

Ramanathan, M., Ferguson, I. D., Miao, W., & Khavari, P. A. (2021). SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00262-0

Kissler, S., Fauver, J. R., Mack, C., Tai, C. G., Breban, M. I., Watkins, A. E., Samant, R. M., Anderson, D. J., Ho, D. D., Grubaugh, N. D., & Grad, Y. (2021). Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2. https://dash.harvard.edu/handle/1/37366884

Parker-Pope, T. (2021, April 22). Do We Still Need to Keep Wearing Masks Outdoors? The New York Times. https://www.nytimes.com/2021/04/22/well/live/covid-masks-outdoors.html?smid=tw-share

Betsch, Cornelia, and Philipp Sprengholz. ‘The Human Factor between Airborne Pollen Concentrations and COVID-19 Disease Dynamics’. PsyArXiv, 16 April 2021. https://doi.org/10.31234/osf.io/hw9gf.

A Marm Kilpatrick. (2021, February 9). Vaccine efficacy in blocking infection & transmission (I think) We can now estimate the (minimum) reduction in transmission from the Moderna vaccine. Thread tl;dr Moderna vaccine blocks >90% (87-93%) of infections & 91% (89-94%) of transmission. *Critiques welcome! Https://t.co/GjQIo3v4oe [Tweet]. @DiseaseEcology. https://twitter.com/DiseaseEcology/status/1359213735424872450

Bosco-Lauth, A. M., Hartwig, A. E., Porter, S. M., Gordy, P. W., Nehring, M., Byas, A. D., VandeWoude, S., Ragan, I. K., Maison, R. M., & Bowen, R. A. (2020). Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2013102117

Wang, C., Wang, S., Chen, Y., Zhao, J., Han, S., Zhao, G., Kang, J., Liu, Y., Wang, L., Wang, X., Xu, Y., Wang, S., Huang, Y., Wang, J., & Zhao, J. (2020). Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection. BioRxiv, 2020.08.12.247338. https://doi.org/10.1101/2020.08.12.247338

Lednicky, J. A., Lauzardo, M., Fan, Z. H., Jutla, A. S., Tilly, T. B., Gangwar, M., Usmani, M., Shankar, S. N., Mohamed, K., Eiguren-Fernandez, A., Stephenson, C. J., Alam, M. M., Elbadry, M. A., Loeb, J. C., Subramaniam, K., Waltzek, T. B., Cherabuddi, K., Morris, J. G., & Wu, C.-Y. (2020). Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients. MedRxiv, 2020.08.03.20167395. https://doi.org/10.1101/2020.08.03.20167395

Heald-Sargent, T., Muller, W. J., Zheng, X., Rippe, J., Patel, A. B., & Kociolek, L. K. (2020). Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19). JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2020.3651

Ou, T., Mou, H., Zhang, L., Ojha, A., Choe, H., & Farzan, M. (2020). Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. BioRxiv, 2020.07.22.216150. https://doi.org/10.1101/2020.07.22.216150

Natalie E. Dean, PhD on Twitter: “Thanks, @MelissaKariWard, for capturing the since deleted tweets. This is why I expressed concern.” / Twitter. (n.d.). Twitter. Retrieved August 2, 2020, from https://twitter.com/nataliexdean/status/1285033748283654146

Wise, Toby, Giorgia Michelini, Tomislav Damir Zbozinek, Cindy C. Hagan, and Dean Mobbs. ‘Development and Validation of the Avoidance of Respiratory Viral Infection Scale (ARVIS)’, 17 July 2020. https://doi.org/10.31234/osf.io/dkc7m.

DELVE group publishes evidence paper on the use of face masks in tackling Coronavirus (COVID-19) pandemic | Royal Society. (2020 May 04). https://royalsociety.org/news/2020/05/delve-group-publishes-evidence-paper-on-use-of-face-masks/

Meyer, A. C. M., Robinson. (2020, May 21). ‘How Could the CDC Make That Mistake?’ The Atlantic. https://www.theatlantic.com/health/archive/2020/05/cdc-and-states-are-misreporting-covid-19-test-data-pennsylvania-georgia-texas/611935/

Jones, T.C., Mühlemann, B., Veith, T., Zuchowski, M., Hofmann, J., Stein, A., Edelmann, A., Corman, V.M., & Drosten, C. (2020). An analysis of SARS-CoV-2 viral load by patient age. Charité Berlin. https://zoonosen.charite.de/fileadmin/user_upload/microsites/m_cc05/virologie-ccm/dateien_upload/Weitere_Dateien/analysis-of-SARS-CoV-2-viral-load-by-patient-age.pdf

Danis, K., Epaulard, O., Bénet, T., Gaymard, A., Campoy, S., Bothelo-Nevers, E., Bouscambert-Duchamp, M., Spaccaferri, G., Ader, F., Mailles, A., Boudalaa, Z., Tolsma, V., Berra, J., Vaux, S., Forestier, E., Landelle, C., Fougere, E., Thabuis, A., Berthelot, P., … Bag, B. C. (2020). Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. Clinical Infectious Diseases, ciaa424. https://doi.org/10.1093/cid/ciaa424

Lohse, S., Pfuhl, T., Berkó-Göttel, B., Rissland, J., Geißler, T., Gärtner, B., Becker, S. L., Schneitler, S., & Smola, S. (2020). Pooling of samples for testing for SARS-CoV-2 in asymptomatic people. The Lancet Infectious Diseases, S1473309920303625. https://doi.org/10.1016/S1473-3099(20)30362-5

Gray, N., Calleja, D., Wimbush, A., Miralles-Dolz, E., Gray, A., De-Angelis, M., Derrer-Merk, E., Oparaji, B. U., Stepanov, V., Clearkin, L., & Ferson, S. (2020). “No test is better than a bad test”: Impact of diagnostic uncertainty in mass testing on the spread of Covid-19 [Preprint]. Epidemiology. https://doi.org/10.1101/2020.04.16.20067884

Wölfel, R., Corman, V.M., Guggemos, W. et al. Virological assessment of hospitalized patients with COVID-2019. Nature (2020). https://doi.org/10.1038/s41586-020-2196-x

Societal Responses to and Preparedness for Emerging Viral Infections – 2020. (n.d.). Novo Nordisk Fonden. Retrieved April 16, 2020, from https://novonordiskfonden.dk/da/grants/societal-responses-to-and-preparedness-for-emerging-viral-infections-2020/